• Loading stock data…

Gene therapy treatment for SMA approved! (Full TA)

Last Updated on June 3, 2019 by Chris Stang

Gene Therapy for SMA– Full technical analysis #VolatilityWatch by follow_the_money on TradingView.com

  • RegenexBio (RGNX) and Novartis (NVS) just received FDA approval of Gene Therapy treatment for Spinal Muscular Atrophy (SMA). 
  • (SMA )Spinal Muscular Atrophy is a disease affecting the motor nerve cells in the spinal cord, taking awaythe ability to walk, eat, or breathe. 
  • Said to be the number one genetic cause of death for infants. 
  • According to a company’s filling, price tag for the treatment is $2.1 million. 
  • Product is called Zolgensma 

Congrats to RegenxBio and Novartis for the huge accomplishment! 


Disclaimer: I currently do not own any position in RGNX nor NVS. This is not advice to buy or sell please do your DD before investing.

Print Friendly, PDF & Email
Spread the word

Reader Interactions

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: